TJ Parker on Building PillPack and Selling to Amazon

TJ Parker tells Harry Stebbings that he grew up around his family’s New Hampshire pharmacy and trained as a pharmacist. Delivering medicines to people’s homes exposed him to a complicated customer experience. His interests in design and technology later met an idea from his father’s pharmacy, which packaged medicines for care facilities.

While studying in Boston, Parker became involved in an MIT business-plan competition and helped start Hacking Medicine with his future co-founder Elliot Cohen. He wondered whether pre-sorted medication could be offered directly to consumers in a better-designed experience. He says the challenge was initially believing he could raise money and build a company.

A successful pitch at Hacking Medicine and entry into Techstars gave him confidence to start PillPack in 2013. He calls its origin iterative rather than a single revelation: pharmacy knowledge, design and technology came together. He believes deep understanding of the customer problem matters more than knowing every industry detail in advance.

Parker jokes about a 2020 dispute with Surescripts and says the company called the FBI while PillPack sought to make health data and pharmacy choice easier for customers. He interprets this as an incumbent trying to portray PillPack negatively. The interview gives his side only and does not establish the allegations, any investigation’s outcome or Surescripts’ position.

More personally, he describes a stable childhood and a desire for greater uncertainty and excitement. As a parent he hopes to provide his children with room to explore and independence. His reflections are about his own family rather than a rule for parenting.

Parker says he is naturally comfortable with uncertainty and has little tactical advice for becoming that way. He encourages people to be honest about the environments in which they thrive. Some founders, he suggests, may discover they prefer another role, though he acknowledges that his own perspective is narrow.

As a young CEO, he felt no need to pretend he could run every function better than the specialists he hired. He concentrated on fundraising, vision and external work while giving leaders room to execute. He says a clear, ambitious vision helped attract people, and that he used judgment and intuition in hiring.

Parker recalls hearing approximate percentages for good and bad hiring decisions but explicitly says he may have invented the figures. His lesson was to revisit a hire quickly when it was not working. He also acknowledges impatience as a personal flaw; the anecdote does not establish hiring accuracy rates.

He believes he and Cohen understood the customer but were naive about industry dynamics and the obstacles incumbents might create. In his view that ignorance helped them begin; founders must nevertheless learn quickly rather than remain naive. He chose consumer technology investors partly to supplement the branding and acquisition skills he lacked.

For venture-funded startups, Parker considers speed of learning essential. He differentiates reversible decisions, which teams should make quickly, from consequential irreversible choices, which deserve sustained deliberation. He says skilled leaders need enough autonomy to act and should bring truly consequential decisions to the CEO.

PillPack’s leadership principle was “assume the best”: trust that colleagues are trying to do good work. Parker contrasts it with his interpretation of Amazon’s “earn trust” principle. He says the former did not materially backfire for his team, while recognizing it could have; the contrast is his cultural interpretation, not an objective description of either company.

He and Cohen sometimes discussed major decisions on long walks over months. One was whether to proactively confront potential network-access problems with incumbents. Parker says they waited rather than acting merely to relieve anxiety, a choice he later connected to the company’s crisis; that is his retrospective interpretation.

Beyond choosing Cohen as co-founder, Parker says a crucial decision was to focus on the end customer. Healthcare has payers and providers with different incentives, but PillPack designed its experience around the person receiving the service. He argues that this focus guided marketing and product choices, while speaking as the company’s founder.

One mistake, he says, was waiting nine months to a year too long to bring in experienced finance and operations leadership. Early operations had grown rapidly through a dedicated leader who could solve problems directly, but the company eventually needed stronger systems and processes. Parker credits an incoming combined CFO and COO with helping the organization scale.

He remembers a board meeting where operational problems became impossible to ignore just before that executive started. Investors had to discuss serious issues while also persuading the new hire that the challenge was worth taking on. The story illustrates his view that a strong early operator can be stretched beyond what an improvised approach can support.

Parker advises founders to identify the central proposition each financing round must prove and hire for that need. For PillPack’s first round, he says, investors largely accepted that the team could open a pharmacy; the uncertain question was whether it could acquire customers online. At that stage customer acquisition mattered more than building a complete executive suite.

He also recommends being deliberate about who attends the recurring executive meeting. In his account, PillPack’s small group gave most discussion time to product and growth while one leader covered operations, finance and other functions. His percentages are a rule of thumb from one company, not evidence that legal or safety work can be neglected.

Parker distinguishes a functional organization, with leaders for engineering, product and other disciplines, from a general-manager model with separate business leaders and teams. He prefers staying functional for as long as possible, arguing that a GM structure creates coordination and administrative overhead. Stebbings notes that some large companies also remain functional; these are organizational judgments, not universal laws.

On compensation, Parker says startup equity can align employees around a shared outcome, while large organizations devote more attention to levels and cash compensation. He views startup work as a different risk-and-reward proposition. Equity value is uncertain and employees’ circumstances and preferences vary.

PillPack raised roughly $4 million in early rounds and launched its product in 2014. Parker says the initial customer-acquisition bet relied on Facebook ads, which appeared to work before the account was suspended under the platform’s pharmacy advertising policy. The company then learned it needed online-pharmacy accreditation.

The accreditation process appeared likely to take about a year, while the startup needed financing sooner. Parker says Fred Destin backed another round before scalable acquisition had been proven, and early Facebook-connected investors also joined. PillPack obtained accreditation in roughly six to eight months, in his account.

He says PillPack raised about $9 million in September 2014, resumed ads around October and saw customer acquisition improve within weeks. He describes the round as roughly $9 million on a $30 million post-money valuation, without special structure, and says a larger round followed. These figures and the causal account are his recollections.

Parker is proud that the early team invested in physical design, working with IDEO on packaging and a pleasant, simple experience. He says the underlying packet function already existed, but the team focused on its presentation and use. He reports that the physical product remained much the same years later.

He explains that pharmacy benefit managers administer prescription benefits and may also operate mail-order pharmacies. Parker believes this created a conflict with PillPack as a delivery competitor. His assertion that there had effectively been no e-commerce pharmacy before PillPack is his characterization and is not established by the interview.

Parker says PillPack initially entered insurance networks like a small independent pharmacy, then drew more attention as volume grew. He recalls termination notices from major pharmacy benefit managers in 2015 and says the company resolved most privately. These events and his interpretation of their motives are his account; the other parties’ positions are not presented.

In early 2016, he says Express Scripts gave notice that PillPack would lose access in two weeks, putting roughly 40% of its revenue at risk. After attempts to engage, PillPack launched a public campaign explaining the issue and collecting customer testimonials. The reported timing, revenue exposure and customer responses are his recollection.

Parker says Express Scripts came to the table after the campaign. During negotiations, another intermediary also threatened access to other networks, in his account. He and Cohen split the work: Parker negotiated with Express Scripts, while Cohen found a replacement intermediary and handled the transition.

He says both problems were resolved before the deadline without losing a contract. Parker believes the public response by customers mattered and describes the moment as existential. This is not an independent legal finding about why any party acted or whether the same path was the only possible one.

Parker adds that the relationship later improved: by the time he left, he says PillPack and Amazon Pharmacy had a good relationship with Express Scripts and had launched a Prime discount program together. That later partnership is part of his account of a changing commercial relationship.

By 2017, PillPack had replaced much of its off-the-shelf pharmacy software and explored offering its infrastructure to other businesses. Parker says a discussion with a large retailer became an acquisition conversation. He and the board saw the capital needed for scale and believed a large retailer could help realize a broader e-commerce pharmacy vision.

In early 2018, Parker says an initial acquisition was close enough that the company stopped a fundraising process. A delay left only about two months of cash, so he restarted discussions with investors and met a potential buyer in Seattle. He says the Amazon meeting revealed strong alignment on the vision.

Parker recalls ultimately asking Amazon for $1 billion and reaching that figure. He says potential buyers offered different structures, including upfront payments and possible earn-outs, but does not provide a complete breakdown of PillPack’s final consideration. He distinguishes the June announcement from closing in September after regulatory review.

He remembers telling the team about the deal more vividly than seeing the money arrive. His claim about immediate movements in public pharmacy stocks is a personal recollection, not independently checked here. He says he has no regret about selling, although he acknowledges the company might conceivably have grown independently.

Parker says the team helped launch Amazon Pharmacy and Amazon Clinic and takes pride in that work. Those are his assessments of products he helped build, not evidence of their medical effectiveness. He describes his own experience at a large company as less comfortable than startup life, while saying Amazon was not necessarily worse than other large organizations.

He says money has given him more time and that family life makes him happy, though he cannot isolate the cause. He mentions buying land for a family farm. In quick questions, he predicts consumers will eventually shop for healthcare more like other services; that is his business view, not medical guidance.

For board relationships he recommends ordinary, ongoing communication during good and bad times. He has changed his mind about how easily people move between startup and large-company environments and advises choosing work suited to one’s personality. He credits early backers Katie Rae and Zen Chu and names Cohen as a valued board member.

Looking toward 2033, Parker jokes about family life and beekeeping, then says he hopes to continue building and helping create useful products. His future plans are aspirations. Stebbings thanks him for sharing his story and the interview ends.